Interestingly, tinengotinib has shown promising clinical benefit in 48 patients with FGFR2 fusion CCA after prior FGFR inhibition, as well as in patients with non-fusion FGFR alterations or wild type, with manageable toxicity.22 Lirafugratinib (RLY-4008), another FGFR2i showed to be efficacious in a phase 1 trial without causing clinically significate hyperphosphatemia or diarrhea.23 Here, FGFR2 is linked to cholangiocarcinoma.